- Solve real problems with our hands-on interface
- Progress from basic puts and calls to advanced strategies
Interactive Options Course
Posted March 25, 2026 at 10:06 am
From NatWest’s divestment to Merck’s $6.7 billion Terns buyout and a wave of bids that got sweetened, pulled, or rejected, companies are refocusing on what drives growth.
March has turned into a sprint for dealmakers, as banks, drugmakers, and money managers buy growth, sell distractions, and ditch deals when the numbers stop adding up.
This week’s headlines show two classic M&A drivers running in parallel: focus and future-proofing. NatWest agreed to sell its HR advisory unit, Mentor, to private equity-backed Empowering People Group as it narrows in on core banking and wealth. Merck, meanwhile, is paying up to $6.7 billion for Terns Pharma to bolster its cancer pipeline ahead of the eventual patent loss for Keytruda, its top seller. But bidders are also getting more cautious: Pepper Money knocked back Challenger after its offer was cut, and Victory Capital walked away from its roughly $8.6 billion pursuit of Janus Henderson amid a more competitive field. Even retailers are reshuffling, with Aurelius reportedly exploring Carrefour’s Belgian unit, per L’Echo.
For markets: Deals come with more strings attached.
Pushback on lower bids is a sign that financing costs and confidence still matter – and that not every “busy M&A tape” is bullish. Rejections and walkaways can cool animal spirits in sectors reliant on leverage, while competitive auctions can still lift valuations for scarce, strategically important assets. The result is a market that rewards clear synergies and punishes wishful math.
The bigger picture: Corporate strategy is getting more defensive.
Boards are acting like portfolio managers: they’re selling units that don’t earn their keep and buying what extends future cash flows. That’s why you’re seeing bank divestments alongside pharma pipeline shopping ahead of patent cliffs. If this continues, expect fewer empire-building megadeals and more targeted transactions where the payoff is easier to explain.
—
Originally Posted March 25, 2026 – Dealmakers Are Busy As Banks, Retailers, And Funds Reshape Portfolios
Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Finimize and is being posted with its permission. The views expressed in this material are solely those of the author and/or Finimize and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Related Articles
Join The Conversation
For specific platform feedback and suggestions, please submit it directly to our team using these instructions.
If you have an account-specific question or concern, please reach out to Client Services.
We encourage you to look through our FAQs before posting. Your question may already be covered!